Cargando…

Clinical and economic burden of pneumococcal disease in US adults aged 19–64 years with chronic or immunocompromising diseases: an observational database study

BACKGROUND: Despite the widespread availability of pneumococcal vaccines, rates of pneumococcal disease are disproportionately high in adults with chronic and immunocompromising conditions. This study investigated pneumococcal disease rates and associated resource utilization and costs in this group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Dongmu, Petigara, Tanaz, Yang, Xiaoqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116536/ https://www.ncbi.nlm.nih.gov/pubmed/30157781 http://dx.doi.org/10.1186/s12879-018-3326-z

Ejemplares similares

Economic burden of pneumococcal disease in children in Liguria, Italy
por: Amicizia, Daniela, et al.
Publicado: (2022)

The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy
por: Barbieri, Elisa, et al.
Publicado: (2022)

2205. Clinical Burden of Pneumococcal Disease in US Adults Aged 65 Years and Above with Chronic or Immunocompromising Conditions
por: Deb, Arijita, et al.
Publicado: (2019)

Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases
por: Imai, Kentaro, et al.
Publicado: (2018)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
por: Vietri, Jeffrey, et al.
Publicado: (2019)

A Retrospective Analysis to Estimate the Burden of Invasive Pneumococcal Disease and Non-Invasive Pneumonia in Children <15 Years of Age in the Veneto Region, Italy
por: Barbieri, Elisa, et al.
Publicado: (2022)

The economic burden of childhood pneumococcal diseases in The Gambia
por: Usuf, Effua, et al.
Publicado: (2016)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

A Retrospective Database Analysis to Estimate the Burden of Acute Otitis Media in Children Aged <15 Years in the Veneto Region (Italy)
por: Barbieri, Elisa, et al.
Publicado: (2022)

PMON64 Economic Burden of Growth Hormone Deficiency in a US Adult Population
por: Smith, Alden, et al.
Publicado: (2022)

Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales
por: Sharomi, Oluwaseun, et al.
Publicado: (2022)

Economic Burden of Pneumococcal Disease in Individuals Aged 15 Years and Older in the Liguria Region of Italy
por: Astengo, Matteo, et al.
Publicado: (2021)

Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany
por: Deb, Arijita, et al.
Publicado: (2022)

The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program
por: Ho, Yi-Chien, et al.
Publicado: (2015)

Economic burden of pneumococcal infections in children under 5 years of age
por: Ceyhan, Mehmet, et al.
Publicado: (2017)

1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
por: Lapidot, Rotem, et al.
Publicado: (2020)

Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age
por: Wasserman, Matt D., et al.
Publicado: (2021)

Pneumococcal Vaccination in Immunocompromised Hosts: An Update
por: Froneman, Claire, et al.
Publicado: (2021)

Regional factors associated with pneumococcal vaccination coverage among U.S. adults with underlying chronic or immunocompromising conditions
por: Liu, Junqing, et al.
Publicado: (2023)

Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020
por: Finelli, Lyn, et al.
Publicado: (2021)

Impact of a guideline-based best practice alert on pneumococcal vaccination rates in adults in a primary care setting
por: McAdam-Marx, Carrie, et al.
Publicado: (2019)

Algorithm development and the clinical and economic burden of Cushing’s disease in a large US health plan database
por: Burton, Tanya, et al.
Publicado: (2015)

1393. Factors Associated with Co-administration of Pentavalent DTaP-IPV/Hib and Monovalent Hepatitis B Vaccine in the United States (US)
por: Petigara, Tanaz, et al.
Publicado: (2020)

Burden of invasive pneumococcal disease in children in Casablanca, Morocco four years after the introduction of pneumococcal vaccination
por: Chikhaoui, Amar, et al.
Publicado: (2022)

Letter to the Editor Regarding “Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age”
por: Feemster, Kristen, et al.
Publicado: (2022)

The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study
por: Siemieniuk, Reed AC, et al.
Publicado: (2011)

Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study
por: Song, Joon Young, et al.
Publicado: (2013)

Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018
por: Hu, Tianyan, et al.
Publicado: (2022)

1399. Parental Perceptions of the Childhood Vaccination Schedule and Combination Vaccines in the United States (US)
por: Petigara, Tanaz, et al.
Publicado: (2020)

Current and projected future economic burden of Parkinson’s disease in the U.S.
por: Yang, Wenya, et al.
Publicado: (2020)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

Modelling the influenza disease burden in people aged 50–64 and ≥65 years in Australia
por: Moa, Aye M., et al.
Publicado: (2021)

Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases
por: Karki, Chitra, et al.
Publicado: (2023)

Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective
por: Earle, Kylie, et al.
Publicado: (2016)

Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis
por: Matthews, Ian, et al.
Publicado: (2020)

Burden of Pneumococcal Disease in Northern Togo before the Introduction of Pneumococcal Conjugate Vaccine
por: Moïsi, Jennifer C., et al.
Publicado: (2017)

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia
por: Aljunid, Syed, et al.
Publicado: (2011)

Clinical and economic burden of pneumococcal disease among adults in Sweden: A population-based register study
por: Zarabi, Natalie, et al.
Publicado: (2023)

1400. Physician Attitudes towards Combination Vaccine Use in Infants up to 24 months of age in the United States (US)
por: Chen, Ya-Ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gd0dulqkab0u73ievgcvogbd4i